TCON News and Press, TRACON Pharmaceuticals Inc. From 12/22/19

Deals and Financings Ally Bridge Group, a Hong Kong-New York life science investment firm, announced it has led $140 million of investments in three new medical device companies, bringing its 18-month total to more than $500 million in private life science companies. ABG's latest investments...

TRACON Pharmaceuticals (NASDAQ: TCON )  +25%  on envafolimab deal . More news on: TRACON Pharmaceuticals, Inc., Care.com, Inc., Marinus Pharmaceuticals, Inc., Stocks on the move, Read more ...

TRACON Pharmaceuticals (NASDAQ: TCON ) is up  39%  premarket on signing a collaborative partnership agreement with 3D Medicines (Beijing) Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd., for the development of envafolimab, also known as KN035, a PD-L1 single...

Company to Host Investor Conference Call Today at 8:30 a.m. ET / 5:30 a.m. PT Envafolimab represents a potential best-in-class PD-L1 inhibitor that is injectable subcutaneously without the need for an adjuvant Envafolimab has been dosed in more than 650 patients in the U.S., China...

SAN DIEGO, Nov. 08, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer as well as wet age-related macular degeneration through a license to Sante...

TRACON Pharmaceuticals, Inc. (TCON) Q3 2019 Earnings Conference Call November 05, 2019 4:30 PM ET Company Participants Charles Theuer – President and Chief Executive Officer Scott Brown – Chief Accounting Officer Conference Call Participants Bert Hazlett –...

Tracon (NASDAQ: TCON ): Q1 GAAP EPS of -$0.17 beats by $0.03 . More news on: TRACON Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer as well as wet age-related macular degeneration through a  license to...

SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration through our license to Santen Pha...

TRACON Pharmaceuticals ( TCON -8.6% ) has entered into a Common Stock Purchase Agreement of up to $15M with Aspire Capital Fund. More news on: TRACON Pharmaceuticals, Inc., Read more ...